SCHEMBL1542597

SCHEMBL1542597

CCOc1cc(NS(C)(=O)=O)ccc1C(=O)Nc1cc(-c2ccc[nH]c2=O)cc(C(C)(C)C)c1OC

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 3/20 0.57
HSD17B10 Q99714 2/20 0.41
RXFP1 Q9HBX9 1/20 0.39
ALDH1A1 P00352 2/20 0.38
MEN1 O00255 2/20 0.38
KMT2A Q03164 2/20 0.38
MAPK1 P28482 1/20 0.38
CRBN Q96SW2 1/20 0.37
MAPK14 Q16539 1/20 0.37
PTPN1 P18031 2/20 0.37
PTPN6 P29350 2/20 0.37
PTPRF P10586 1/20 0.37
PTPN2 P17706 1/20 0.37
PTPN11 Q06124 1/20 0.37
LMNA P02545 2/20 0.36
KDM4E B2RXH2 1/20 0.36
MAPT P10636 1/20 0.36
HPGD P15428 1/20 0.36
TSHR P16473 1/20 0.36
ATM Q13315 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1542475 0.93 CYP3A4 (0.56) CYP3A4RXFP1ALDH1A1MEN1KMT2A
SCHEMBL1542733 0.91 CYP3A4 (0.54) CYP3A4RXFP1ALDH1A1MEN1KMT2A
SCHEMBL2129460 0.88 CYP3A4 (0.59) CYP3A4ALDH1A1MEN1KMT2AMAPK1
SCHEMBL2127612 0.88 CYP3A4 (0.58) CYP3A4ALDH1A1MEN1KMT2AMAPK1
SCHEMBL1542876 0.88 CYP3A4 (0.58) CYP3A4ALDH1A1MEN1KMT2AMAPK1
SCHEMBL2128872 0.87 CYP3A4 (0.57) CYP3A4ALDH1A1MEN1KMT2AMAPK1
SCHEMBL1542369 0.85 CYP3A4 (0.65) CYP3A4ALDH1A1MEN1KMT2AMAPK1
SCHEMBL1542477 0.83 CYP3A4 (0.59) CYP3A4CRBNMAPK14TRPV1
SCHEMBL1542202 0.83 CYP3A4 (0.60) CYP3A4ALDH1A1MEN1KMT2AMAPK1
SCHEMBL1542683 0.81 CYP3A4 (0.61) CYP3A4RXFP1ALDH1A1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8273773-B2 Heterocyclic antiviral compounds ROCHE PALO ALTO LLC (US) 2012-09-25 US claimed
EP-2307372-B1 HETEROCYCLIC ANTIVIRAL COMPOUNDS HOFFMANN LA ROCHE (CH) 2012-04-25 EP claimed
EP-2307372-A1 HETEROCYCLIC ANTIVIRAL COMPOUNDS F. Hoffmann-La Roche AG (CH) 2011-04-13 EP claimed
WO-2010010017-A1 HETEROCYCLIC ANTIVIRAL COMPOUNDS F. HOFFMANN-LA ROCHE AG (CH) 2010-01-28 WO claimed
US-20100021423-A1 Heterocyclic antiviral compounds ROCHE PALO ALTO LLC 2010-01-28 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100021423-A1 Heterocyclic antiviral compounds POLR2A, RRM2B, RRP1B CYP3A4 528/4885HSD17B10 1679/4885RXFP1 2058/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.